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Correct protein folding and inhibition of protein aggregation is facilitated by a cellular
“quality control system” that engages a network of protein interactions including
molecular chaperones and the ubiquitin proteasome system. Key chaperones involved
in these regulatory mechanisms are the protein disulfide isomerases (PDI) and their
homologs, predominantly expressed in the endoplasmic reticulum of most tissues.
Redox changes that disrupt ER homeostasis can lead to modification of these enzymes
or chaperones with the loss of their proposed neuroprotective role resulting in an
increase in protein misfolding. Misfolded protein aggregates have been observed in
several disease states and are considered to play a pivotal role in the pathogenesis
of neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease,
and Amyotrophic Lateral sclerosis. This review will focus on the importance of the
thioredoxin-like CGHC active site of PDI and how our understanding of this structural
motif will play a key role in unraveling the pathogenic mechanisms that underpin these
neurodegenerative conditions.
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Introduction
Protein disulfide isomerases (EC 5.3.4.1) are key metabolic proteins which primarily reside in
the endoplasmic reticulum (ER) and operate in synergy with other chaperones, such as glucose-
regulated protein (78 kDa) (GRP78) that controls the processing and correct folding of proteins
(Wilkinson and Gilbert, 2004). Expression of PDI has also been reported outside the ER, in the
mitochondria, nucleus, cytosol and cell surface (Yoshimori et al., 1990; Koehler et al., 2006; El
Hindy et al., 2014). PDI forms part of the thioredoxin superfamily, which catalyze the formation
and breakage of disulfide bonds, through thiol:disulfide exchange, facilitating correct refolding of
the protein by rearranging the configuration of disulfide bonds (Figure 1) (Tu et al., 2000). These
proteins have also associated roles as chaperones in refolding without enzymatic involvement.
The functional diversity of the PDI family depends on its metabolic substrates, the redox
environment, but more importantly their characteristic thioredoxin domain-like structures,
which govern the redox thiol-disulfide isomerase and chaperone activity. Depletion of PDI in
mammalian cells results in a delay in disulfide bond formation of secretory proteins, high-
lighting its vital role in oxidative protein folding (Rutkevich et al., 2010). Neurodegenera-
tive diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic
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FIGURE 1 | The mechanistic details of PDI as (A) an oxidase (B) a
reductase (C) interaction of reduced PDI with ERO1 (D) an
isomerase. These mechanisms are complex, governed in part by its
intriguing structure but also the pKa of the involved cysteine residues and
the redox microenvironment. (A) Operating as an oxidase, forming new
disulfide bonds, PDI in its oxidized form, is targeted through the
nucleophilic cysteine of the substrate, forming a mixed disulphide. The
substrate is then released oxidized after donating its reducing equivalents
to PDI. (Bi) As a reductase, the N-terminal cysteine of PDI, which has a
low pKa (approximately 4.5), targets its substrate disulfide bond through a
nucleophilic attack, forming a mixed disulfide. Now, the substrate thiol is
free to interact with another disulfide bond. This results in the oxidation of
PDI. (Bii) Alternatively, reduced PDI can be re-oxidized by GSSG or an
oxidoreductase, the ER flavo-oxidase Ero1 (its preferred substrate), but
peroxiredoxins are also efficient. The kinetic rates of reaction of PDI in vitro
are dependent on the substrate and the GSH/GSSG ratio. (C) In brief,
reduced PDI, generated after reaction 1(dotted line), is oxidized by the a′
domain (reaction 2), finally, reoxidation of the a′ domain is catalyzed by
Ero1 and channels the electrons to final acceptors such as molecular
oxygen (reaction 3/4) (D) Rearranging of disulfide bonds is less understood
but incorrect disulfide bonding undergoes isomerization creating the correct
pattern of disulfide bond formation.
lateral sclerosis (ALS) share several common pathological char-
acteristics, in particular, the abnormal accumulation of misfolded
proteins forming inclusions, where a common role for PDI has
been assigned (Kim et al., 2000; Muchowski, 2002; Tuite and
Melki, 2007). This review will focus on the function of PDI in
protein folding and the impact of increased cellular stress on its
proposed neuroprotective role.
Structure of Human PDI Dictates its
Functional Diversity
The PDI family has 21 members, all of which have
thioredoxin-like fold structures, with most including 1–3
redox-active -CXXC- motifs (Ellgaard and Ruddock, 2005;
Appenzeller-Herzog and Ellgard, 2008; Hatahet and Ruddock,
2009). The individual domains of human PDI [Figure 1C (a, a′,
b, and b′)] have been resolved using NMR (PDB codes; 1Mek,
1X5C, 3BJ5, and 2K18) (Kemmink et al., 1996, 1999; Denisov
et al., 2007; Nguyen et al., 2008). However, it was not until the
recent crystallization of the three-dimensional structure of yeast
PDI [4◦C (PDB:2B5E) and 22◦C (PDB:3BOA)] and human
PDI (hPDI) [oxidized (PDB:4EL1) and reduced (PDB:4EKZ)]
that insight into how these domains operate cooperatively was
detailed (Tian et al., 2006; Wang et al., 2013). hPDI has four
thioredoxin-like domains (a, a′, b, and b′), where two of these
(a and a′) have a catalytic redox-active –CGHC- motif (Wang
et al., 2013). In yeast (the structure resolved at 4◦C) and hPDI,
the a/a′ domains face each other in a “U-shaped” structure and
are solvent exposed allowing interaction with their respective
substrates (Tian et al., 2006; Wang et al., 2013). The b domains
confer substrate specificity and form a hydrophobic rigid base
connecting the two flexible a domains. The a′ and b′ domain are
connected through a 19 amino acid inter-domain link, called the
x-linker, which is predicted to promote flexibility, influencing
substrate binding (Wang et al., 2010). Another key feature is the
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highly-acidic C-terminus, which is involved in calcium binding
and contains the ER-retrieval motif KDEL. In hPDI, the folds
of the domains show conformational differences in the reduced
and oxidized form, where the distance between the two active
site -CXXC- regions increases from 27.6 to 40.3 Å, offering a
more open structure exposing the hydrophobic areas of the b
domains when oxidized, supporting a role for redox in chaperone
PDI activity (Wang et al., 2013). Reported by several groups,
homo-dimerization of the bb′ domain, regulated by the x-linker
region, is suggested to block substrate access, regulating PDI
activity (Byrne et al., 2009; Wallis et al., 2009; Bastos-Aristizabal
et al., 2014). Molecular dynamic simulation of three-dimensional
structures suggested that in solution hPDI may adopt more rigid
structures facilitated by inter-domain salt-bridges, encouraging
inter-domain disulfide bond formation (Yang et al., 2014). These
exciting advances in structural analysis have expanded our
knowledge of this highly complex protein and have accelerated
our move toward understanding the functional diversity of PDI
(The mechanistic details of PDI are summarized in Figure 1).
Molecular Chaperones, PDI, and Cellular
Stress
The cell responds to an increase in immature or misfolded
proteins through a concerted protein network response, involv-
ing the upregulation of several molecular chaperones that pre-
vent protein aggregation, termed the unfolded protein response
(UPR), followed by ER-associated degradation (ERAD), which
specifically recognizes terminally misfolded proteins. Molecular
chaperones such as the heat shock proteins (e.g., HSP70 and
HSP90) are ubiquitously expressed in all cells and in all subcellu-
lar compartments. They represent a diverse group of proteins and
are characterized based on their dependence on ATP, holdases,
are ATP dependent and foldases, are independent of ATP, the
former considered the first line of defense (reviewed by Niforou
et al., 2014). Bip/GPR78 and PDI, among other chaperones, func-
tion in the ER stress response as neuro-protectors by alleviating
the level of misfolded proteins. However, by mechanisms which
involve increased cellular stress, these “quality control systems”
fail leading to the aggregation and deposition of mis-folded pro-
teins, which not only result in loss of protein function but also
lead to cell toxicity and ultimately cell death, a pathway linked to
many neurodegenerative diseases.
Excess reactive oxygen and nitrogen species (ROS/RNS)
generated through oxidative metabolism, or triggered from envi-
ronmental toxins and also normal aging can cause an imbalance
between the production of ROS/RNS and the cell’s defense sys-
tems, including anti-oxidant enzymes (such as the glutaredoxin
system), glutathione, and molecular chaperones (Nakamura and
Lipton, 2009). Neurons are particularly vulnerable due to their
comparatively low levels of certain antioxidants and reliance
on energy from ROS/RNS-generating mitochondrial metabolism
(Mattson et al., 2002). Pertinent to this review is the modifica-
tion of PDI through S-nitrosylation, the addition of a nitric oxide
(NO) moiety to a reactive thiol (-SH) group (SNO-PDI). Under
normal physiological conditions, S-nitrosylation modulates the
function of target proteins, playing a dynamic role in numerous
biological processes. In contrast, under pathological conditions,
stress induced S-nitrosylation of certain proteins, including PDI,
can alter protein function triggering a cascade of events result-
ing in neuronal cell death that ultimately results in neurodegen-
eration (Nakamura and Lipton, 2007; Nakamura et al., 2013).
Increased PDI expression has been reported in neurodegen-
erative diseases, to ease ER stress from the accumulation of
misfolded proteins, however, the neuroprotective effect of its
disulfide-isomerase and chaperone activity can be inhibited by
S-nitrosylation (Uehara et al., 2006; Andreu et al., 2012), dis-
cussed below with respect to AD, PD, and ALS (summarized in
Figure 2).
SNO-PDI Colocalizing with Amyloid β and
Tau: Implications in Alzheimer’s Disease
The key morphology of AD includes cerebral atrophy, β-amyloid
(Aβ) deposits, and neuritic changes such as neurofibrillary tan-
gles (NFT) (reviewed in Hardy, 2003), which manifests clinically
as a progressive loss in cognition, mood changes, and memory
loss (Alzheimer, 1907). These NFTs contain hyperphosphory-
lated, microtubule-associated tau and are linked to the clinical
progressive stages of AD (Braak and Braak, 1991; Morishima-
Kawashima and Ihara, 2002). Several metabolic mechanisms
also contribute to disease progression, including glutamate tox-
icity, calcium overload, an increase in cellular stress linked
with mitochondrial and ER dysfunction, protein misfolding and
a dysregulation of autophagy (Sattler and Tymianski, 2000;
Calabrese et al., 2006; Nakamura and Lipton, 2007; Nixon, 2007;
Nakamura and Lipton, 2008).
The accumulation of misfolded proteins and influx of cellular
Ca2+, associated with AD, can cause ER stress in neurons and are
considered to contribute to AD (Schroder, 2008). A role for PDI
in contributing to AD pathology has been supported through evi-
dence of its co-localization with NFT and the dystrophic neurites
of senile plaques in AD patient brain tissues, particularly in the
hippocampus and frontal lobe, areas most affected by AD (Honjo
et al., 2010, 2012). Co-localization of PDI with tau to the ER was
also reported in the SH-SY5Y cell line, a model of AD pathology
(Xu et al., 2013). Interestingly, a small number of NFTs immuno-
positive for PDI was found in normal control brains, but these
were few and scattered (Honjo et al., 2010). However, it may indi-
cate that in normal aging brains ER stress can result in misfolded
proteins, where a role for PDI is likely.
In AD, an increase in cellular ROS/RNS is associated with
alterations in Aβ metabolism (Dalle-Donne et al., 2006; Man-
gialasche et al., 2009). These changes in cellular stress also tar-
gets susceptible proteins and damages mitochondria (related to
Aβ production). ROS-damaged mitochondria results in the oxi-
dation of mitochondrial DNA (genes of oxidative phosphoryla-
tion are reduced), lipids [increased 4-hydroxy-2-nonenal (HNE)]
(Hardas et al., 2013) and proteins (nitration of enolase) leading
to mitochondrial dysfunction and impaired cellular respiration
(Castegna et al., 2002). Moreover, mitochondria-derived ROS can
also enhance Aβ formation, contributing to cell death (Leuner
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FIGURE 2 | Increased expression of PDI and regulation of
protein misfolding in neurodegenerative disease. An increase in
cellular stress originating from both environmental and intracellular
sources initiates a cascade of defenses to protect the cell against
damage, including increased expression of molecular chaperones,
initiation of the ER-stress response, where the role of PDI strongly
features. The response of PDI generates a signature pattern across
all neurodegenerative conditions indicating a key role for this protein
as a neuroprotector against cellular stress. However, S-nitrosylation
impacts activity and compromises this protective role leading to an
increase in misfold proteins, creating aggregates, contributing to cell
death.
et al., 2012). Together with the presentation of specific mutations
in the presenilin-1 gene, overt mitochondrial damage, where
a role for cellular ROS predominates, is considered to factor
strongly in the pathogenesis of AD (reviewed in García-Escudero
et al., 2013).
Important to this review is the impact of increased cellu-
lar ROS on PDI activity and its role in AD. In AD brain an
increased expression of PDI was reported, however, pathophys-
iological relevant amounts of S-nitrosylated PDI was also noted
(Uehara et al., 2006; Hoffstrom et al., 2010; Andreu et al., 2012).
In these studies, S-nitrosylation of PDI, through the redox active
thiols of the a and a′ domain (Figure 1C), inhibited enzyme
activity and resulted in the accumulation of poly-ubiquitinated
proteins, an increase in ER stress and induction of apoptosis
(Uehara et al., 2006; Nakamura and Lipton, 2009). ER stress can
initiate a cascade of events including activation of the UPR, which
aims to slow down protein synthesis and increase protein fold-
ing capacity (reviewed in Salminen et al., 2009). For reasons not
entirely understood this system becomes overwhelmed result-
ing in the increase in protein aggregation, a contributing factor
to several neurodegenerative conditions. S-glutathionylation of
PDI, induced through RNS, may also factor in this mechanism
(Townsend et al., 2009). The accrual of unfolded proteins in the
ER lumen is in fact sufficient to produce ROS/RNS, suggesting a
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vicious cycle of ER stress and local oxidative stress finally leading
to cell death when unresolved (Malhotra and Kaufman, 2007).
The role of PDI in preventing aggregates, such as Aβ, extends
also to NFT, where PDI inhibited nucleation and elongation of
Tau244−372 fibrillization in SH-SY5Y cells, again illustrating its
role as a neuroprotector (Xu et al., 2013).
A homolog of PDI, protein disulfide isomerase P5 (P5), was
found to also co-localize with tau in NFTs (Honjo et al., 2014).
Knock-down of PDI or P5 in SH-SY5Y cells resulted in decreased
cell viability under ER stress (Honjo et al., 2014). Like PDI, the
P5 protein was also shown to be S-nitrosylated in AD patient
brains, however, unlike that reported for PDI, expression levels
of P5 were significantly decreased (Honjo et al., 2014). ERp57,
another PDI family protein, has been reported in the CSF of
AD patients physically associated with amyloid-β (Erickson et al.,
2005), suggesting a potential role as a carrier protein that pre-
vents aggregation of Aβ. Together, these studies clearly indicate
a direct association between SNO-PDI, and protein misfolding,
understanding of which will identify potential new therapeutic
targets for AD.
α-Synuclein Aggregation Regulated by
SNO-PDI in Parkinson’s Disease
Build-up of protein aggregates strongly features in PD pathol-
ogy. Here, cytoplasmic Lewy bodies, which stain for aggregated
α-synuclein in the substantia nigra, results in the clinical pre-
sentation of bradykinesia, rest tremor, rigidity, gait, and postural
abnormalities (Spillantini et al., 1997; Baba et al., 1998; Kawa-
mata et al., 2001; Neystat et al., 2002). This is also a heteroge-
neous disease where protein aggregation and increased cellular
stress, among others, contribute to disease pathology (reviewed
in Nakamura and Lipton, 2011). Pharmacological models of PD
in vitro have illustrated that enhanced production of ROS is
the main cause of ER stress, where a significant up-regulation
of PDI and ERp57 are linked to a global ER stress response
(Ryu et al., 2002; Holtz and O’Malley, 2003; Holtz et al., 2006).
These findings have also been confirmed in α-synuclein trans-
genic mouse models, as well as in brain tissue derived from PD
patients (Conn et al., 2004; Colla et al., 2012). Although clinically
distinct from AD, S-nitrosylated PDI was also reported in PD
brain tissue, where S-nitrosylation of PDI inhibited its enzymatic
activity, resulting in the accumulation of polyubiquinated pro-
teins, indicating similarities in mechanisms underlying different
neurodegenerative conditions (Uehara et al., 2006).
In vitro studies have shown that PDI colocalized and inter-
acted with α-synuclein in dopaminergic MES cells, and under
normal physiological conditions, forms a complex with α-
synuclein, in the process, preventing abnormal aggregation
(Honjo et al., 2011a; Xu et al., 2014). However, when PDI was
S-nitrosylated, this interaction was disturbed, resulting in α-
synuclein oligomerization, indicating a key role for the a and a′
domains in this mechanism (Wu et al., 2014). The authors con-
cluded that PDI can relieve neurodegeneration by decreasing α-
synuclein aggregation, but when S-nitrosylated the consequential
dysfunction of PDI results in α-synuclein aggregation. Chemical
modification of PDI promotes the aggregation and build-up
of the minor Parkinsonian-specific biomarker synphilin-1 in a
NO dependent manner (Uehara et al., 2006; Uehara, 2007).
However, over-expression of wild-type PDI (non-SNO-PDI)
reduced synphilin-1-containing aggregates in SHSY-5Y cells
(Uehara et al., 2006). A recent paper examining the effect
of SNO-PDI formation on α-synuclein aggregation and Lewy-
like neurite formation, found that in addition to SNO-PDI
formation activating α-synuclein aggregation, it was also seen
to provoke co-localization and in parallel the formation of
α-synuclein:synphilin-1-containing Lewy-body-like aggregates,
supporting the role of SNO-PDI in PD pathogenesis (Kabiraj
et al., 2014). Although the functional contribution of PDIs to
the pathogenesis of PD in vivo requires further validation, col-
lectively these studies illustrate that up-regulation of PDI rep-
resents a protective response to abnormal protein aggregation,
contributing to the re-establishment of protein homeostasis,
whereas S-nitrosylation clearly impacts protein aggregation and
deposition.
SNO-PDI, SOD1, NOX, and Amyotrophic
Lateral Sclerosis
ALS is characterized by the accumulation of cytoplasmic aggre-
gated ubiquitinated proteins in motor neurons and surrounding
oligodendrocytes, which clinically presents as progressive mus-
cle weakness, typically with a 3–5 year survival (reviewed in
Blokuis et al., 2013). Mutations in 16 genes have been identi-
fied to be associated with classical ALS, including mutations in
superoxide dismutase (SOD1), TARDBP, fused in sarcoma (FUS),
UBQLN2, profiling, and C9ORF72, but these are rare (Ferraiuolo
et al., 2011; Rademakers and Blitterswijk, 2012; Chen et al., 2013).
Approximately 90% of all ALS cases are sporadic, with the second
most frequent, familial ALS, attributed to dominantly inherited
mutations in Cu/Zn SOD1 (Rosen, 1993). The major inclusions
associated with both familial and sporadic ALS are the TDP-43-
positive ubiquitinated protein aggregates that accumulate in the
cytoplasm, where PDI was also shown to reside (Honjo et al.,
2011b). Another inclusion associated with ALS, FUS is normally
located in the nucleus but in ALS is redistributed to the cytoplasm
(Dormann et al., 2010). In NSC-34 cells, mutant FUS expres-
sion triggers ER stress and co-localizes with PDI (Farg et al.,
2012).Moreover, PDI was shown to co-localize with FUS-positive
ubiquitinated inclusions, in human ALS patient spinal cords,
supporting the in vitro cell models.
A significant increase in PDI expression, alongside other
ER stress markers such as ERp57, was reported in ALS spinal
cord and CSF compared to controls and also in the G93A
SOD1 mouse model of ALS (Atkin et al., 2006, 2008; Massig-
nan et al., 2007; Honjo et al., 2011a). This increase in PDI
expression is not just limited to neurons, but has also been
observed in the microglia and astrocytes of murine mod-
els (Jaronen et al., 2013). However, in ALS, PDI is also S-
nitrosylated impacting its neuroprotective role, again sharing
common mechanistic traits to AD and PD (Walker et al., 2010;
Jeon et al., 2014). In ALS mouse and cell models, overexpres-
sion of PDI decreases both the accumulation of SOD1 aggre-
gates and neuronal cell death, whereas inhibition of PDI using
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bacitracin or siRNA knockdown increases the formation of
aggregates (Atkin et al., 2006, 2008; Walker et al., 2010; Jeon
et al., 2014). Furthermore, when production of NO genera-
tion via NOS was blocked using N-nitro-L-arginine, the for-
mation of SNO-PDI and mutant SOD1 aggregates significantly
decreased (Chen et al., 2013), but interestingly studies using
the PDI redox-mutant suggest that it is the chaperone activ-
ity of PDI that was responsible (Jeon et al., 2014). The thera-
peutic effects of Reticulon-4A, found to have a protective role
against disease onset and progression in an ALS mouse model,
were associated with intracellular redistribution of PDI, sup-
porting the role of PDI as a therapeutic target (Yang et al.,
2009).
In vivo ALS studies have indicated that NADPH oxidase
(NOX) activation and superoxide production are elevated in
microglia and may contribute to motorneuron death, through
increased cellular S-nitrosylation (Wu et al., 2006). In vitro stud-
ies showed that PDI acts as an important regulator of NOX
activation and subsequent ROS production in microglial cells,
suggesting that an up-regulation of PDI may not just have a
protective role in protein aggregation but also in regulating UPR-
triggered NOX activation, in a cell-type specific manner (Jaro-
nen et al., 2013). Proteomic screening identified PDI and ERp57
as biomarkers for ALS, with ERp57 highlighted for its poten-
tial to monitor disease progression (Nardo et al., 2011). Due
to the key role PDI appears to play in ALS, a genome associa-
tion study examined the effects of two specific single-nucleotide
polymorphisms (SNPs) in the P4HB gene, which codes for PDI,
which showed a significant association with familial ALS, sug-
gesting that P4HB is a modifier gene in ALS susceptibility and
may present a potential therapeutic target (Kwok et al., 2013).
The same study also identified two genotypes and one diplotype
that modify disease survival. These findings are consistent with
the view that PDI expression is clearly linked to ALS pathology
and either de-nitrosylation of PDI or up-regulation of total PDI
may provide a therapeutic benefit in ALS.
Conclusion
An increase in the generation of ROS/RNS through exter-
nal and internal cellular mechanisms can overwhelm the anti-
oxidant and chaperone systems contributing to an increase in
cellular calcium, mitochondrial dysfunction, protein misfold-
ing/aggregation leading to cell death. This pathogenic pathway
shares common features across all neurodegenerative conditions
despite clear genetic links that differentiate between them. A
role for PDI in protein misfolding has emerged as a key link
to understanding how these aggregates accumulate in the brain
with similar patterns of colocalization of PDI with disease specific
aggregates. Despite clear evidence that protein aggregation in
central to the pathology of neurodegenerative conditions, many
questions remain unanswered. How do these models of pro-
tein misfolding translate in vivo? Is it possible to generate a
therapeutic translation to mimic increased PDI expression that
is not subject to S-nitrosylation? Or will increased expression
of PDI stimulate unfavorable metabolic reactions, attenuating its
potential role as a target therapeutic.
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